Brits buy Dorland Global in $20M deal

Share this article:
Publicly held Huntsworth PLC, based in London, has purchased Dorland Global Corp., for $20.7 million in cash, extending the reach of its healthcare division into the US market.

The acquisition covers its two units, Dorland Global Health Communications and Dorland Global Public Relations.

The sale price for the previously independent agency will be shared by 10 shareholders, along with co-founders Harry and Rita Sweeney. The deal also may include deferred compensation based on Dorland profits for the year ending Dec. 31, 2007, plus a payment to be made based on three-year profits through 2010, Huntsworth said.

The maximum price was capped at $50 million. Dorland reported 2006 gross profit of $3.5 million and gross assets of $11 million as of year end.
The existing management team will continue to operate the business, reporting to David Rowley, chief executive of Huntsworth Health.

Dorland will serve as a US footprint for the Huntsworth Health division, the largest healthcare firm in the UK.

In an interview with MM&M, Rita Sweeney said being part of a larger agency will help Dorland “take on and pitch and win larger global accounts…that was the whole strategy to begin with.”

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in News

Email Newsletters

More in News

Judge blocks FDA bid to allow generic Precedex

Judge blocks FDA bid to allow generic Precedex

The US District Court for Maryland granted Hospira a temporary restraining order (TRO) against FDA, after the agency determined that potential generic competitors of the company's injectable sedation drug Precedex ...

GSK drug gets aplastic anemia indication

GSK drug gets aplastic anemia indication

Promacta was previously indicated for chronic immune thrombocytopenia.

Five things for Pharma Marketers to know: Wednesday, August 27

Five things for Pharma Marketers to know: Wednesday, ...

Allergan sets a shareholder voting date, Novo describes the types of acquisitions it will consider, and the AstraZeneca-Pfizer talks can now reopen.